Prs48 - Cost – Effectiveness Analysis of Vilanterol/Fluticasone Furoate for Asthma Treatment in the Russian Federation

Value in Health- United Kingdom

doi 10.1016/j.jval.2018.09.2442

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Prs38 - Cost-Consequence Analysis of Fluticasone Furoate/Vilanterol for Asthma Management in Spain: An Analysis Based on the Salford Lung Study in Asthma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2018English

Integrated Safety and Efficacy Analysis of Once-Daily Fluticasone Furoate for the Treatment of Asthma

Respiratory Research
PulmonaryRespiratory Medicine
2016English

Once-Daily Fluticasone Furoate/Vilanterol Combination Versus Twice-Daily Budesonide/Formoterol Combination in the Treatment of Controlled Stable Asthma: A Randomized Crossover Trial

Journal of Asthma and Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2019English

Fluticasone Furoate: Once-Daily Evening Treatment Versus Twice-Daily Treatment in Moderate Asthma

Respiratory Research
PulmonaryRespiratory Medicine
2011English

Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2020English

Prs50 - Cost-Effectiveness Analysis of Surfactant Therapy for the Treatment of Respiratory Distress Syndrome Newborn in the Russian Federation

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Fluticasone Furoate/Vilanterol Once Daily Improves Night-Time Awakenings in Asthma Patients With Night Symptoms; Post-Hoc Analyses of Three Randomized Controlled Trials

Journal of Asthma
Child HealthAllergyPerinatologyImmunologyMedicinePediatricsPulmonaryRespiratory Medicine
2018English

Human Medicines European Public Assessment Report (EPAR): Revinty Ellipta, Fluticasone Furoate / Vilanterol, Asthma, Date of Authorisation: 02/05/2014, Revision: 16, Status: Authorised

Case Medical Research
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy